Presentation is loading. Please wait.

Presentation is loading. Please wait.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors  Neal I. Lindeman,

Published byBritt-Marie Jonsson Modified over 5 years ago

Similar presentations

Presentation on theme: "Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors  Neal I. Lindeman,"— Presentation transcript:

1 Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors  Neal I. Lindeman, MD, Philip T. Cagle, MD, Dara L. Aisner, MD, PhD, Maria E. Arcila, MD, Mary Beth Beasley, MD, Eric H. Bernicker, MD, Carol Colasacco, MLIS, SCT(ASCP), Sanja Dacic, MD, PhD, Fred R. Hirsch, MD, PhD, Keith Kerr, MB, ChB, David J. Kwiatkowski, MD, PhD, Marc Ladanyi, MD, Jan A. Nowak, MD, PhD, Lynette Sholl, MD, Robyn Temple-Smolkin, PhD, Benjamin Solomon, MBBS, PhD, Lesley H. Souter, PhD, Erik Thunnissen, MD, PhD, Ming S. Tsao, MD, Christina B. Ventura, MPH, MT(ASCP), Murry W. Wynes, PhD, Yasushi Yatabe, MD, PhD  Journal of Thoracic Oncology  Volume 13, Issue 3, Pages (March 2018) DOI: /j.jtho Copyright © 2018 College of American Pathologists, American Society for Investigative Pathology, Association for Molecular Pathology, and the International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Forest plot of sensitivity and specificity for immunohistochemistry (IHC)-based determination of ROS1 rearrangement positivity compared with fluorescence in situ hybridization. Pooled estimate of sensitivity and specificity based on bivariate analysis of included studies. All included studies used an IHC staining intensity of at least 2+ with a D4D6 antibody to define ROS1 rearrangement positivity. Abbreviations: FN, false-negative; FP, false-positive; TN, true-negative; TP, true-positive. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2018 College of American Pathologists, American Society for Investigative Pathology, Association for Molecular Pathology, and the International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 Forest plot of sensitivity and specificity for immunohistochemistry-based determination of ALK translocation positivity compared with fluorescence in situ hybridization. Pooled estimate of sensitivity and specificity based on bivariate analysis of included studies. Included studies assessed 5A4, D5F3, or either 5A4 or D5F3 antibodies with positivity cutoffs based on either presence of any staining or staining intensity. Abbreviations: FN, false-negative; FP, false-positive; neg, negative; pos, positive; TN, true-negative; TP, true-positive. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2018 College of American Pathologists, American Society for Investigative Pathology, Association for Molecular Pathology, and the International Association for the Study of Lung Cancer Terms and Conditions

4 Figure 3 Forest plot of sensitivity and specificity for various assays determining EGFR mutation positivity with cell-free DNA compared with tumor tissue. Pooled estimate of sensitivity and specificity based on bivariate analysis of included studies. Four included studies compared tumor tissue samples with plasma samples using the same detection system,234,235,242,243 and a fifth study232 obtained plasma samples from patients with known EGFR and KRAS tumor mutation status. Abbreviations: ARMs, amplification refractory mutation system; ddPCR, droplet digital PCR; FN, false-negative; FP, false-positive; PCR, polymerase chain reaction; PNA/LNA, peptide nucleic acid–locked nucleic acid; TN, true-negative; TP, true-positive. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2018 College of American Pathologists, American Society for Investigative Pathology, Association for Molecular Pathology, and the International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors  Neal I. Lindeman,"

Similar presentations

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors Neal I. Lindeman, Philip T. Cagle, Mary Beth.

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors Neal I. Lindeman, Philip T. Cagle, Mary Beth.
EGFR Mutations in Lung Adenocarcinomas

EGFR Mutations in Lung Adenocarcinomas
Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.

Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.
Droplet Digital PCR for Absolute Quantification of EML4-ALK Gene Rearrangement in Lung Adenocarcinoma  Qiushi Wang, Xin Yang, Yong He, Qiang Ma, Li Lin,

Droplet Digital PCR for Absolute Quantification of EML4-ALK Gene Rearrangement in Lung Adenocarcinoma  Qiushi Wang, Xin Yang, Yong He, Qiang Ma, Li Lin,
ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New.

ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New.
Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis  Sarah Cargnin, PhD,

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis  Sarah Cargnin, PhD,
Real-Time Polymerase Chain Reaction for Detecting Bacterial DNA Directly from Blood of Neonates Being Evaluated for Sepsis  Jeanne A. Jordan, Mary Beth.

Real-Time Polymerase Chain Reaction for Detecting Bacterial DNA Directly from Blood of Neonates Being Evaluated for Sepsis  Jeanne A. Jordan, Mary Beth.
Adrian G. Sacher, MD, Kimberly M. Komatsubara, MD, Geoffrey R

Adrian G. Sacher, MD, Kimberly M. Komatsubara, MD, Geoffrey R
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors  Neal I. Lindeman, Philip T. Cagle, Mary.

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors  Neal I. Lindeman, Philip T. Cagle, Mary.
T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis  Hugo Gortais,

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis  Hugo Gortais,
Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non–Small-Cell.

Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non–Small-Cell.
Multiplex Preamplification of Serum DNA to Facilitate Reliable Detection of Extremely Rare Cancer Mutations in Circulating DNA by Digital PCR  Jennifer.

Multiplex Preamplification of Serum DNA to Facilitate Reliable Detection of Extremely Rare Cancer Mutations in Circulating DNA by Digital PCR  Jennifer.
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.

EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.
Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential Sensitivity 

Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential Sensitivity 
Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M

Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors  Neal I. Lindeman,

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors  Neal I. Lindeman,
Clinicopathologic Analysis of ROS1-Rearranged Non–Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm  Heounjeong Go, MD, PhD, Dong-Wan Kim,

Clinicopathologic Analysis of ROS1-Rearranged Non–Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm  Heounjeong Go, MD, PhD, Dong-Wan Kim,
A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib  Trish Thorne-Nuzzo, BS, Crystal.

A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib  Trish Thorne-Nuzzo, BS, Crystal.
Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor  Alessandra Bearz, MD, Elisa.

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor  Alessandra Bearz, MD, Elisa.

Similar presentations

Ads by Google